Description: Lumos Pharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for severe, rare, and genetic diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency. The company has a licensing agreement with Ellipses Pharma Limited for the development of and rights to commercialize nanoparticle formulations of two therapeutics for oncology indications. Lumos Pharma, Inc. was founded in 2011 and is headquartered in Austin, Texas.
Home Page: www.lumos-pharma.com
LUMO Technical Analysis
4200 Marathon Boulevard
Austin,
TX
78756
United States
Phone:
512 215 2630
Officers
| Name | Title |
|---|---|
| Mr. Richard J. Hawkins | CEO & Chairman |
| Dr. John C. McKew Ph.D. | Chief Scientific Officer & Pres |
| Ms. Lori D. Lawley CPA | CFO & Principal Accounting Officer |
| Lisa Miller | Sr. Director of Investor Relations |
| Mr. Bradley J. Powers J.D. | Chief Compliance Officer & Gen. Counsel |
| Mr. Carl W. Langren | Consultant |
| Mr. Aaron Schuchart B.B.A., CPA, M.B.A. | Chief Bus. Officer |
| Dr. David B. Karpf B.A., M.D. | Chief Medical Officer |
| Mr. Eddie L. Varnado M.B.A. | VP of Fin. & Corp. Controller |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4045 |
| Price-to-Sales TTM: | 22.4545 |
| IPO Date: | 2011-11-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 32 |